
ORPHENADRINE CITRATE - orphenadrine citrate tablet, extended release Physicians Total Care, Inc.

Orphenadrine Citrate Extended-Release Tablets

DESCRIPTION

Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate is (\pm) -N,N-Dimethyl-2-[(o-methyl- α -

phenylbenzyl)oxy]ethylamine citrate (1:1) having molecular formula $C_{18}H_{23}NO \cdot C_6H_8O_7$ and molecular weight of 461.51. It has the following structural formula:



Each tablet for oral administration contains 100 mg orphenadrine citrate.

Each Orphenadrine citrate extended-release tablet contains the following inactive ingredients: hydroxypropyl methylcellulose, lactose monohydrate and magnesium stearate.

CLINICAL PHARMACOLOGY

The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense muscles in man. Orphenadrine citrate also possesses anti-cholinergic actions.

INDICATIONS AND USAGE

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

CONTRAINDICATIONS

Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis.

Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

WARNINGS

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned

```
accordingly.
```

PRECAUTIONS

Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.

Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias.

Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.

Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Adverse reactions of orphenadrine are mainly due to the mild anti-cholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.

DRUG ABUSE AND DEPENDENCE

Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

OVERDOSAGE

Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

DOSAGE AND ADMINISTRATION

Adults

Two tablets per day; one in the morning and one in the evening.

HOW SUPPLIED

Orphenadrine citrate extended-release tablets 100 mg are round, white tablets, debossed GG 931 on one side and plain on the reverse side and are supplied as:

Bottles of	NDC 54868-
10	4102-1
Bottles of	NDC 54868-
30	4102-2
Bottles of	NDC 54868-
50	4102-4
Bottles of	NDC 54868-
60	4102-5
Bottles of	NDC 54868-
100	4102-3

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container.

01-2010M

8100

GIN-480-00

Manufactured by

Sandoz Inc.

Princeton, NJ 08540

for GAVIS Pharmaceuticals, LLC

400 Campus Drive

Somerset, NJ 08873

Relabeling and Repackaging by: Physicians Total Care, Inc. Tulsa, OK 74146

PRINCIPAL DISPLAY PANEL

Orphenadrine Citrate Extended-Release Tablets 100 mg Rx only



ORPHENADRINE CITRATE

orphenadrine citrate tablet, extended release

	oduct Informatio	n						
Pro	duct T ype		HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54868				3-4102(NDC:43386-480)	
Rou	te of Administratio	n	ORAL					
Act	ive Ingredient/A	ctive Moi	ety					
Ingredient Name Basis of S							rength	Strengt
ORI	PHENADRINE CITRA	TE (UNII: X0A	40 N8 I4S) (ORPHE	ENADRINE - UI	NII:AL805090G9)	ORPHENADRIN	E CITRATE	100 mg
Ina	ctive Ingredient	S						
			Ingredient	Name			Stre	ngth
	ROMELLOSES (UNI							
	TOSE MONOHYDR.							
MAG	GNESIUM STEARATI	E (UNII: 7009	7M6I30)					
_	duct Characteri	stics						
				S corro		20	ccoro.	
Col	Dr	white	0	Score			score	
Col Sha	or pe		D	Size	In	10 n	nm	
Col Sha Flav	or pe ⁄or	white	D		le	10 n		
Col Sha Flav	or pe	white	D	Size	e	10 n	nm	
Col Sha Flav Con	or pe ⁄or tains	white	D	Size	le	10 n	nm	
Col Sha Flav Con	or pe vor tains ckaging	white ROUN		Size Imprint Cod		10 n GG	nm 931	d Date
Col Sha Flav Con Pac	or pe /or .tains ckaging Item Code	ROUN ROUN Pac	kage Descriptio	Size Imprint Cod	le Aarketing Start Da	10 n GG	nm	d Date
Col Sha Flav Con Pac #	or pe vor tains ckaging Item Code DC:54868-4102-1	white ROUN Pac 10 in 1 BC	kage Descriptic TTLE, PLASTIC	Size Imprint Cod		10 n GG	nm 931	d Date
Col Sha Flav Con # 1 N 2 N	or pe /or .tains ckaging Item Code	white ROUN ROUN	kage Descriptic TTLE, PLASTIC TTLE, PLASTIC	Size Imprint Cod		10 n GG	nm 931	d Date
Col Sha Flav Con H 1 N 2 N 3 N	or pe vor tains tkaging Item Code DC:54868-4102-1 DC:54868-4102-2	white ROUN ROUN 10 in 1 BC 30 in 1 BC 100 in 1 B	kage Descriptic TTLE, PLASTIC	Size Imprint Cod		10 n GG	nm 931	d Date
Coli Sha Flav Con # 1 N 2 N 3 N 4 N	or pe vor tains Ckaging Item Code DC:54868-4102-1 DC:54868-4102-2 DC:54868-4102-3	white ROUN ROUN IO IO	kage Descriptic TTLE, PLASTIC DTTLE, PLASTIC OTTLE, PLASTIC	Size Imprint Cod		10 n GG	nm 931	d Date

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANDA	ANDA040284	04/17/2000			

Labeler - Physicians Total Care, Inc. (194123980)

Establishment					
Name	Address	ID/FEI	Business Operations		
Physicians Total Care, Inc.		194123980	relabel, repack		

Revised: 1/2010

Physicians Total Care, Inc.